Cytomegalovirus Infection Pipeline

DelveInsight’s, “Cytomegalovirus (CMV) Infection Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Cytomegalovirus (CMV) Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Cytomegalovirus (CMV) Infection: Understanding

Cytomegalovirus (CMV) Infection: Overview

Cytomegalovirus (CMV) is a common virus belonging to the herpesvirus family, often causing asymptomatic infections in healthy individuals. However, it can be severe in immunocompromised patients and lead to congenital infections, which can result in long-term complications like hearing loss and developmental disabilities. CMV is widespread, with infection rates varying globally, and it has a unique ability to evade the immune system. While typically dormant after the initial infection, CMV can reactivate, posing ongoing health risks, particularly for vulnerable populations. In addition to causing congenital conditions, CMV has been linked to the development of certain cancers, including mucoepidermoid carcinoma and potentially prostate cancer. It remains a significant challenge due to its ability to persist in the body and evade immune responses.

 

Following primary infection, CMV establishes latency in myeloid cells, where it remains dormant for the host's lifetime. The immune system, especially cytotoxic T-cells, plays a crucial role in controlling viral replication and reactivation. However, when the immune system is compromised—such as in organ transplant recipients, HIV-infected individuals, or those on immunosuppressive therapy—CMV can reactivate. This reactivation results in viral replication and the release of new virions into the bloodstream and various bodily fluids, causing symptoms ranging from mild to life-threatening, particularly in immunocompromised patients. CMV's ability to evade the immune system and persist in a latent state contributes to its complex pathophysiology and challenges in treatment.

 

Cytomegalovirus (CMV) infection can be diagnosed through a variety of tests, including blood, saliva, urine, and tissue samples, depending on the patient's age, symptoms, and medical condition. Blood tests are commonly used in adults with symptoms and to determine whether a pregnant person has been previously infected with CMV. For newborns, saliva or urine tests are preferred, with PCR testing of saliva being the standard for diagnosing congenital CMV infection. Urine tests help confirm the diagnosis. Tissue samples, including biopsies, can also be analyzed using immunohistochemistry to identify CMV. Additionally, prenatal tests such as amniocentesis can be used to detect CMV infection in an unborn baby, while a shell vial assay can help confirm the presence of CMV in cell cultures. Early diagnosis is crucial for managing CMV, especially in pregnant individuals, newborns, or those with weakened immune systems.

 

Several antiviral agents, including cidofovir, foscarnet, ganciclovir, and valganciclovir, have been approved for the treatment of CMV infection. In immunocompetent patients, CMV infections are usually mild or asymptomatic and generally do not require specific treatment, with symptomatic management being sufficient. However, antiviral therapy is recommended for severe cases of CMV mononucleosis, CMV infection, or CMV disease in immunocompromised individuals. The use of antiviral drugs is not without risk, as they can be toxic, and their potential side effects must be carefully weighed against the benefits. For patients who have received organ transplants from CMV-infected donors, prophylactic treatment with valganciclovir or ganciclovir is recommended, along with regular serological monitoring, to prevent the development of life-threatening infections.

"Cytomegalovirus (CMV) Infection- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cytomegalovirus (CMV) Infection pipeline landscape is provided which includes the disease overview and Cytomegalovirus (CMV) Infection treatment guidelines. The assessment part of the report embraces, in depth Cytomegalovirus (CMV) Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cytomegalovirus (CMV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cytomegalovirus (CMV) Infection R&D. The therapies under development are focused on novel approaches to treat/improve Cytomegalovirus (CMV) Infection.

 

Cytomegalovirus (CMV) Infection Emerging Drugs Chapters

This segment of the Cytomegalovirus (CMV) Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Cytomegalovirus (CMV) Infection Emerging Drugs

 

• mRNA-1647: ModernaTX, Inc.

mRNA-1647 comprises six mRNAs encoding two antigens in one vaccine and is designed to protect against CMV infection. Of the six mRNAs, five encode the subunits of the CMV pentamer complex and one mRNA encodes the Glycoprotein B (gB) protein, both of which are highly immunogenic. The pentamer complex is important for CMV entry into a variety of cells, including epithelial cells, while gB is important for entry into all susceptible cells including fibroblasts. A vaccine that produces an immune response against both pentamer and gB has the potential to prevent CMV entry into a range of target cell types and thus prevent primary and congenital infections. Unlike a protein-based vaccine, mRNA-1647 instructs the body’s own cells to manufacture the antigens, resulting in functional antigens that mimic those presented to the immune system by CMV during a natural infection. Preclinical data previously published in Vaccine showed that vaccination with mRNA-1647 in animal models elicited potent and durable neutralizing antibody titers. Currently, the drug is in Phase III stage of its development for the treatment of Cytomegalovirus (CMV) Infection.

 

• Cytomegalovirus vaccine (Triplex) : Helocyte

The Triplex vaccine by Helocyte is a multi-antigen vaccine designed to induce a robust and durable virus-specific T-cell response against cytomegalovirus (CMV) infections, particularly in recipients of allogeneic hematopoietic stem cell transplants (HSCT) and solid organ transplants (SOT). The vaccine utilizes the Modified Vaccinia Ankara (MVA) vector to express three immunodominant CMV proteins: UL83 (pp65), UL123 (IE1), and UL122 (IE2). By targeting these proteins, Triplex stimulates a host antiviral response, enhancing both CD4+ and CD8+ T-cell responses. This mechanism of action helps control CMV infections by promoting cellular immunity, which is crucial for managing and preventing CMV-related complications in immunocompromised patients.. Currently, the drug is in Phase II stage of its development for the treatment of Cytomegalovirus (CMV) Infection.

 

• VBI-1501: VBI Vaccines Inc.

VBI-1501 by VBI Vaccines Inc. is a prophylactic cytomegalovirus (CMV) vaccine candidate developed using the company's proprietary enveloped virus-like particle (eVLP) technology. This vaccine presents a modified form of the glycoprotein B (gB) found on CMV, which plays a crucial role in viral entry into host cells. The mechanism of action (MOA) of VBI-1501 involves inducing protective CMV-neutralizing antibodies that can block infection in multiple cell types, including fibroblasts and epithelial cells. By eliciting these antibodies, VBI-1501 aims to prevent CMV infection by mimicking the natural immune response observed in individuals who have developed immunity through natural infection. Currently, the drug is in Phase I stage of its development for the treatment of Cytomegalovirus (CMV) Infection.

Further product details are provided in the report……..

 

Cytomegalovirus (CMV) Infection: Therapeutic Assessment

This segment of the report provides insights about the different Cytomegalovirus (CMV) Infection drugs segregated based on following parameters that define the scope of the report, such as:

 

Major  Players in Cytomegalovirus (CMV) Infection

There are approx. 15+ key companies which are developing the therapies for Cytomegalovirus (CMV) Infection. The companies which have their Cytomegalovirus (CMV) Infection drug candidates in the most advanced stage, i.e. Phase III include, ModernaTX, Inc.

 

Stay ahead with in-depth analysis of the Cytomegalovirus Infections Market Forecast-discover emerging therapies, epidemiology data and growth opportunities.

Cytomegalovirus (CMV) Infection Clinical Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Cytomegalovirus (CMV) Infection Route of Administration

Cytomegalovirus (CMV) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

 

Cytomegalovirus (CMV) Infection Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Cytomegalovirus (CMV) Infection Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Cytomegalovirus (CMV) Infection: Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Cytomegalovirus (CMV) Infection therapeutic drugs key players involved in developing key drugs. 

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cytomegalovirus (CMV) Infection drugs.

 

Cytomegalovirus (CMV) Infection Report Insights

• Cytomegalovirus (CMV) Infection Pipeline Analysis
• Cytomegalovirus (CMV) Infection Therapeutic Assessment
• Cytomegalovirus (CMV) Infection Unmet Needs
• Impact of Cytomegalovirus (CMV) Infection Drugs

 

Cytomegalovirus (CMV) Infection Report Assessment

• Pipeline Product Profiles
• Cytomegalovirus (CMV) Infection Therapeutic Assessment
• Cytomegalovirus (CMV) Infection Pipeline Assessment
• Inactive drugs assessment
• Cytomegalovirus (CMV) Infection Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cytomegalovirus (CMV) Infection drugs?
• How many Cytomegalovirus (CMV) Infection drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cytomegalovirus (CMV) Infection?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cytomegalovirus (CMV) Infection therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Cytomegalovirus (CMV) Infection and their status?
• What are the key designations that have been granted to the emerging drugs?